Caplin Point announces completion of unannounced USFDA inspection

The inspection was concluded with zero observations

Caplin Point listed on Forbes Asia’s “200 Best under a Billion” for 2024

The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity

Zydus receives final approval from USFDA for Valbenazine Capsules

Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)

Merck to acquire investigational B-Cell depletion therapy from Curon Biopharmaceutical

CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases

Merck's aarogya health program positively impacts communities in Patalganga

Aarogya program aims to improve the overall health outcomes for the community by offering comprehensive health screenings, diagnostic support, and increased health awareness

Merck inks MoU with Aragen to facilitate supply of equipment and technologies for mAb

This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule

Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.

Jan Aushadhi Kendras have sold Rs. 5,600 Cr medicines over last 10 years

The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024

32 projects completed under PLI Scheme for promotion of domestic manufacturing of Critical KSMs/DIs and APIs

Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme

Bio-economy is going to spearhead India’s future growth story: Dr. Jitendra Singh